2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Pages

Selected funding rounds

Date Company Profile Round
Sep 2011 Crescendo Bioscience Inc Series C
Aug 2011 Verinata Health Inc Series C
Aug 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Aug 2011 Affinium Pharmaceuticals Ltd Developing a novel class of antibiotics. N/A
Aug 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Aug 2011 Affinium Pharmaceuticals Ltd Developing a novel class of antibiotics. N/A
Aug 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Aug 2011 Affinium Pharmaceuticals Ltd Developing a novel class of antibiotics. N/A
Jul 2011 Roka Bioscience Inc Series C
28 Jun 2011 Nimbus Discovery LLC A computational technology-based drug discovery company. Series A
28 Jun 2011 Nimbus Discovery LLC A computational technology-based drug discovery company. Series A
Jun 2011 Aegea Medical Inc AEGEA Medical, Inc. develops and sells medical devices for treatment of abnormal uterine bleeding. Series B
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
Jun 2011 Regenesis Biomedical Inc Series C
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
May 2011 TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C
May 2011 Delenex Therapeutics AG Series A

Pages

Selected companies

Company type: 
Verax Biomedical is a privately held, venture backed medical products company.
Company type: 
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
Company type: 
Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers.
Company type: 
A biotechnology company seeking to become the leader in therapeutic vaccines, focused initially on the treatment of cancer
Company type: 
Biopharmaceutical company developing and commercializing tumor-selective drugs for cancer patients.
Company type: 
An innovative biopharmaceutical company developing biologics to target autoimmune/ inflammatory diseases.
Company type: 
Specialty pharmaceuticals company.
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products